particles count.

attyloid is a biotech spin-off built on strong scientific expertise in the field of protein misfolding and aggregation. We have developed an ultra-sensitive quantitative technology platform with value-adding potential as biomarker of CNS diseases and drug effect assaying, development and QC of biologicals, and counting of viral particles.

Latest attyloid news

As by April 2020, attyloid moved to the Life Science Center in Düsseldorf, Germany.

The team is looking forward to working side by side with other great biotech companies. Very fruitful environment!

attyloid is looking for collaborations in SARS-CoV-2 R&D

  • absolute titer determination
  • decontamination studies
  • assay development
  • seroconversion assays